Subject demographics by response to 0.4 μM epinephrine, PR study
Subject characteristic . | Less than 60% aggregation . | At least 60% aggregation . | P . |
|---|---|---|---|
| Mean age, y, ± SD | 34.3 ± 10.6 | 33.5 ± 9.1 | .619 |
| % women | 64.0 | 81.6 | .015 |
| Race, % of group | .179 | ||
| African-American | 37.3 | 55.0 | |
| White | 37.3 | 30.6 | |
| Hispanic | 16.9 | 10.2 | |
| Asian | 7.1 | 4.1 | |
| Other | 1.3 | 0.0 | |
| Mean body mass index, kg/m2, ± SD | 26.6 ± 5.8 | 27.3 ± 6.2 | .442 |
| Women using oral contraceptives, % | 25.4 | 22.5 | .701 |
| Premenopausal women, % | 81.2 | 85 | .794 |
| Premenopausal women in luteal phase, % | 54.9 | 71.4 | .107 |
| Current smokers, % | 12.4 | 8.2 | .396 |
| Subjects with hypertension, % | 5.9 | 0 | .081 |
| Mean fibrinogen, mg/dL*, ± SD | 324 ± 91 | 364 ± 110 | .011 |
Subject characteristic . | Less than 60% aggregation . | At least 60% aggregation . | P . |
|---|---|---|---|
| Mean age, y, ± SD | 34.3 ± 10.6 | 33.5 ± 9.1 | .619 |
| % women | 64.0 | 81.6 | .015 |
| Race, % of group | .179 | ||
| African-American | 37.3 | 55.0 | |
| White | 37.3 | 30.6 | |
| Hispanic | 16.9 | 10.2 | |
| Asian | 7.1 | 4.1 | |
| Other | 1.3 | 0.0 | |
| Mean body mass index, kg/m2, ± SD | 26.6 ± 5.8 | 27.3 ± 6.2 | .442 |
| Women using oral contraceptives, % | 25.4 | 22.5 | .701 |
| Premenopausal women, % | 81.2 | 85 | .794 |
| Premenopausal women in luteal phase, % | 54.9 | 71.4 | .107 |
| Current smokers, % | 12.4 | 8.2 | .396 |
| Subjects with hypertension, % | 5.9 | 0 | .081 |
| Mean fibrinogen, mg/dL*, ± SD | 324 ± 91 | 364 ± 110 | .011 |
For subjects with less than 60% aggregation, n = 310; for those with at least 60% aggregation, n = 49. No subjects had diabetes.
For logistical reasons, assays were performed on the first 308 subjects, 266 with less than 60% aggregation and 42 with at least 60% aggregation.